Photo via New York Post

‘Massive breakthrough’ as new pancreatic cancer treatment can make tumors disappear: ‘We’ve never seen such a thing’

Read the original at New York Post ↗
Cite

Yang, A. (2026, November 20). ‘Massive breakthrough’ as new pancreatic cancer treatment can make tumors disappear: ‘We’ve never seen such a thing’. New York Post. https://nypost.com/2026/11/20/health/pancreatic-cancer-combo-made-tumors-disappear-massive-breakthrough/

Dated from the outlet's own feed. Check the original for its byline.

New York Post · collected 2026-11-20 · by Allie Yang

Quick Summary

A new treatment for pancreatic cancer, involving the drug daraxonrasib combined with chemotherapy, has shown unprecedented results in clinical trials. In these trials, the combination therapy caused tumors to stop growing or shrink significantly, with some tumors becoming undetectable. Specifically, 8.2% of patients had no trace of cancer by the end of the study, and more than 76% of participants survived for at least one year. Dr. Wungki Park from Memorial Sloan Kettering describes this as a “massive breakthrough” in cancer treatment, highlighting the potential for the drug to become a first-line treatment option.
Written by AI on 2026-11-21, from this article's own text only (the story summary below draws on all the coverage).
See how they differ ↓

AI analysis

Story summary

A new drug called daraxonrasib, when combined with chemotherapy, has shown significant promise in treating advanced pancreatic cancer. In early clinical trials presented at the EORTC-NCI-AACR Symposium in Barcelona, tumors either shrank or stopped growing in almost all of the 61 patients who had recently been diagnosed with the disease that had spread to other parts of the body. Specifically, the cancer became undetectable in one in 12 patients. Although doctors emphasize that the pill is not yet a cure and its long-term effectiveness is still unknown, they consider it a major breakthrough, as pancreatic cancer has the lowest survival rate of all common cancers in the UK, with only about 3% of patients surviving five years after diagnosis. Cancer Research UK hailed the results as "the biggest leap forward in decades." Longer studies will be needed to determine the drug's full potential.

Written for “Pancreatic Cancer Pill Breakthrough” on 2026-11-21, grounded in this article and the 3 other(s) covering the same event.

How they differ

4 outlets covered “Pancreatic Cancer Pill Breakthrough”.

What each outlet says

One AI summary per outlet of its latest article on this story, written from that article alone and checked against it. Open the article for the outlet's own words.

New York PostThis outlet20 Nov

A new treatment for pancreatic cancer, involving the drug daraxonrasib combined with chemotherapy, has shown unprecedented results in clinical trials. In these trials, the combination therapy caused tumors to stop growing or shrink significantly, with some tumors becoming undetectable. Specifically, 8.2% of patients had no trace of cancer by the end of the study, and more than 76% of participants survived for at…

‘Massive breakthrough’ as new pancreatic cancer treatment can make tumors disappear: ‘We’ve never seen such a thing’ (this article)
BBC20 Nov

Experts are heralding a daily pill called daraxonrasib as a major breakthrough in pancreatic cancer treatment, with some patients showing undetectable tumors on scans. In a trial involving 61 recently diagnosed patients with advanced pancreatic cancer, tumors stopped growing in 90% of participants, and for around 8%, or one in 12, tumors became undetectable. While this is considered highly promising, doctors…

Massive hope for pancreatic cancer pill after trial saw tumours vanish →
The Guardian20 Nov

Doctors are celebrating early results from a trial of a new pill called daraxonrasib for pancreatic cancer, which showed that in one in 12 patients, the cancer became undetectable. In the trial involving 61 patients with advanced cancer that had spread, tumours stopped growing in 90% of cases, and over 60% saw their tumours shrink or disappear. Dr. Wungki Park, who presented the findings at a symposium in Barcelona…

Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’ →
Fox News21 Nov

A new drug combination involving an experimental pill called daraxonrasib and standard chemotherapy has shown promising results in treating advanced pancreatic cancer. In a phase 1/2 trial presented at the EORTC-NCI-AACR Symposium in Barcelona, this combination shrank tumors or halted their growth in 90.2% of 61 patients, with 60.7% experiencing tumor shrinkage, including 8.2% who saw complete response. The median…

New drug combo shrinks tumors in most patients facing aggressive cancer type →

Compared with similar articles

This article reads unscored and hedges 6% of its claims. Each row says how that neighbour differs.
The Guardian
Hedges 3 of 19 claims Outlet record 64/100

Story

Pancreatic Cancer Pill Breakthrough
Health · 4 article(s) covering the same event. See how they differ ↑
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
31
sentences that state something as happening or true
Uncertain
6%
2 of 31 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
66/100
New York Post's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
4
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-11-21 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

New York Post · 21831 article(s) · 42 correction(s) detected
Running correction rate · 42 correction(s)

Who wrote this

Allie Yang
42 article(s) here · 1 carrying a prediction
Pickup soccer, it turns out, is the mayor’s Achilles’ heel.
But when used in combination with chemo, it could revolutionize treatment, new data suggests.
With it, experts say more people will be accurately diagnosed with obesity and better able to get the treatments suitable for their situation.
But over 36,000 people will die from prostate cancer this year, a vast majority from metastatic, advanced cancer.
How could this happen to someone in “perfect health, perfect shape,” as her dad described?
Wietrzyk will be participating in the Elite 15, a series of competitions to qualify for the Hyrox World Championships.
However, they say those thresholds may be outdated — particularly for BPA, which they observed at relatively high levels.
The lump grew so large she “couldn’t even zip my jacket up …
If you need to go under the knife, a key tool to prepare could already be in your bedside table.
What researchers found USC researchers had a group of 365 fish-averse adults, 55 to 80 years old and at increased risk for Alzheimer’s, take fish oil daily to see if it would help them avoid cognitive decline over the course of two years.
Also by Allie Yang
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 42 articles by Allie Yang →

Topics

Lenox Hill Hospital Memorial Sloan Kettering Northwell Park Rasonque

Subjects

Park ORG · 2× Wungki Park PERSON · 2× Alan Rickman PERSON · 1× Alex Trebek PERSON · 1× Jerry Springer PERSON · 1× Lenox Hill Hospital ORG · 1× Memorial Sloan Kettering ORG · 1× Nicholas Hornstein PERSON · 1× Northwell GPE · 1× Patrick Swayze PERSON · 1×

Narrative

“People with treatment-naïve metastatic pancreatic cancer urgently need more effective treatment options, given the limited clinical benefit of current chemotherapy regimens,” said Dr. Alan Sandler, chief development officer of Revolution Medicines, the maker of daraxonrasib.
framing: assertive · carried by 1 article(s) · first seen 2026-11-21
But when used in combination with chemo, it could revolutionize treatment, new data suggests.

Claims (31 extracted, 2 hedged)

A pill made to treat one of the deadliest cancers was already setting high expectations after its approval in August. asserted
pill → make → August
But when used in combination with chemo, it could revolutionize treatment, new data suggests. uncertain
data → use → treatment
Clinical trials show the combination is not only stopping pancreatic cancer tumors from growing and spreading — it can eliminate them entirely. asserted
it → show → them
“This is the closest to cure,” said oncologist Dr. Wungki Park, when presenting the findings. asserted
Park → cure → findings
“We’ve never seen such a thing.” asserted
We → see → thing
Advertisement Previous research on the drug, daraxonrasib (sold as Rasonque), showed incredible promise. asserted
research → sell → promise
The drug alone was shown to double survival time for pancreatic cancer, a total of 13.2 months up from 6.7 months. asserted
drug → show → months
Now, scientists are seeing how daraxonrasib works with chemo. asserted
daraxonrasib → see → chemo
In clinical trials, this combination caused a vast majority of tumors to stop growing, and some shrank so much they became undetectable. asserted
they → cause → tumors
The results are a “a massive, massive breakthrough” in the fight against the third-deadliest cancer, according to Dr. Wungki Park, an oncologist at Memorial Sloan Kettering, who presented the findings. uncertain
who → accord → findings
The study is part of a phase 1/2 clinical trial combining daraxonrasib with gemcitabine and nab-paclitaxel, two chemotherapy drugs, to treat pancreatic cancer that has metastasized, or spread to other parts of the body (stage 4). asserted
that → combine → body
When using both therapies, nine in 10 patients had tumors shrink or remain stable, while three in five patients saw significant tumor shrinkage or disappearance. asserted
patients → use → shrinkage
About 8.2% (one in 12) patients had no detectable cancer at the end of the study. asserted
patients → have → study
More than 76% of participants survived past one year on the treatment. asserted
% → survive → treatment
Park noted the findings were significant because this study had a median follow up of 18.3 months, which is much longer than that of previous research. asserted
which → note → research
This means we now have a better idea of how long patients benefit from the treatment, and how long tumors stay shrunk. asserted
tumors → mean → treatment
Advertisement “With longer follow-up and a larger patient population, we are seeing a notable combination of high response rates, including deep complete responses, and durable disease control, with median progression-free survival exceeding one year,” said Park. asserted
Park → see → year
He adds that this data presents “compelling rationale” to evaluate the drug as a “potential first-line treatment option” for pancreatic cancer. asserted
data → add → cancer
Daraxonrasib is a tablet taken orally once a day. asserted
Daraxonrasib → take → ?
It works by targeting a mutated protein called KRAS, which Dr. Nicholas Hornstein, a medical oncologist at Northwell’s Lenox Hill Hospital, said acts like a “stuck accelerator” in cancer cells, telling them to keep growing when they should stop. asserted
they → work → them
Pancreatic cancer is resistant to a number of treatments, including chemotherapy, radiation, targeted therapy and immunotherapy, making it notoriously difficult to treat. asserted
it → include → chemotherapy
Overall just 13.7% of patients survive the cancer past five years, making it the third-deadliest cancer. asserted
it → survive → years
Alex Trebek, Patrick Swayze, Alan Rickman and Jerry Springer are just a few of the many who died within that time frame from this disease. asserted
who → die → disease
In April, former Sen. Ben Sasse shared about his experience on the drug to treat his stage 4 pancreatic cancer. asserted
Sasse → share → cancer
He experienced a relatively common side effect of skin toxicity. asserted
He → experience → toxicity
In clinical trials, dermatologic toxicity occurred in 86% of patients treated with this drug — 10% had grade 3 or severe reactions. asserted
% → occur → reactions
“I take it orally, but it’s a nasty drug,” he said. asserted
he → take → it
“It causes crazy stuff like my body can’t grow skin and so I bleed all out of a whole bunch of parts of me that shouldn’t be bleeding.” asserted
that → cause → me
He was diagnosed with cancer in December 2025 and was given three to four months to live, which he far exceeded. asserted
he → diagnose → which
In September, he revealed some tumors are now developing resistance to treatment. asserted
tumors → reveal → treatment
“People with treatment-naïve metastatic pancreatic cancer urgently need more effective treatment options, given the limited clinical benefit of current chemotherapy regimens,” said Dr. Alan Sandler, chief development officer of Revolution Medicines, the maker of daraxonrasib. asserted
Sandler → need → daraxonrasib
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support